PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18042053-10 2007 Both statins significantly reduced plasmatic levels of CRP (3.18 +/- 2.43 mg/dL [T0] vs. 1.31 +/- 1.67 mg/dL [T2] with rosuvastatin [P < 0.01], 7.53 +/- 7.46 mg/dL [T0] vs. 2.92 +/- 2.06 mg/dL [T2] with atorvastatin [P < 0.01]). Rosuvastatin Calcium 119-131 C-reactive protein Homo sapiens 55-58 18042053-11 2007 Relative reduction of CRP levels was -50.57% with rosuvastatin versus -36.28% with atorvastatin (P N.S.). Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 22-25 17984166-6 2007 RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 211-229 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 57-75 17920365-0 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Rosuvastatin Calcium 31-43 C-reactive protein Homo sapiens 95-113 17920365-4 2007 Significantly more patients treated with rosuvastatin achieved the combined end point of LDL cholesterol <70 mg/dl and CRP <2 mg/L compared with atorvastatin by the end of the study period (58% vs 37%; p <0.001 vs atorvastatin). Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 122-125 17920365-5 2007 In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 15-18 17223112-6 2007 Rosuvastatin also produced superior dose-related decreases in median high-sensitivity C-reactive protein (22.9-38.5%). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 86-104 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Rosuvastatin Calcium 32-44 C-reactive protein Homo sapiens 187-205 17595889-2 2007 In the present study we investigated the possibility that rosuvastatin directly affected CRP expression in stimulated human hepatocytes. Rosuvastatin Calcium 58-70 C-reactive protein Homo sapiens 89-92 17595889-7 2007 Rosuvastatin reduced CRP expression by 32% and 46% in Hep3B and PHH, respectively. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 17595889-9 2007 At 1 microM, rosuvastatin reduced CRP mRNA by 73% compared to IL-6-stimulated cells. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 34-37 17595889-12 2007 CONCLUSIONS: Our results show a direct inhibitory effect of rosuvastatin on IL-6-induced expression of CRP in liver cells. Rosuvastatin Calcium 60-72 C-reactive protein Homo sapiens 103-106 17595889-14 2007 The effects of rosuvastatin in reducing the levels of CRP in plasma may have clinical utility in addition to its effects on atherogenic lipoproteins. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 54-57 16193198-6 2005 High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). Rosuvastatin Calcium 73-85 C-reactive protein Homo sapiens 17-35 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 114-126 C-reactive protein Homo sapiens 28-46 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 184-196 C-reactive protein Homo sapiens 28-46 17338662-4 2007 Also results from the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study could provide further evidence for the use of rosuvastatin in individuals with traditional and emerging CHD risk factors, such as an elevated high sensitivity C-reactive protein level. Rosuvastatin Calcium 190-202 C-reactive protein Homo sapiens 303-321 16858347-7 2006 Treatment of men with ischemic heart disease with rosuvastatin (10 mg for 3 months) led to achievement of target values of LDLCH in 77% of them, to significant lowering of concentrations of CRP and interleukin 6, and to improvement of endothelial function. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 190-193 16253600-0 2005 Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 C-reactive protein Homo sapiens 62-80 15050187-6 2004 A large-scale, randomized clinical trial-Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-will test whether rosuvastatin therapy will reduce incident cardiovascular disease in subjects with elevated plasma hs-CRP concentrations who do not meet current criteria for initiation of lipid-lowering drug therapy. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 276-279 14636905-8 2003 High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Rosuvastatin Calcium 95-107 C-reactive protein Homo sapiens 17-35 14609996-0 2003 Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 165-183 34956579-1 2021 Objective: To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Rosuvastatin Calcium 102-114 C-reactive protein Homo sapiens 76-79 34956579-11 2021 Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis. Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 61-64 33913752-0 2021 The Effect of Rosuvastatin on plasma/serum levels of high sensitivity C-reactive protein, Interleukin-6 and D-dimer in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 70-88 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 C-reactive protein Homo sapiens 142-160 33652637-11 2021 In this study, rosuvastatin reduced the level of C-reactive protein (CRP) but did not reduce the rate of POAF. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 49-67 33652637-11 2021 In this study, rosuvastatin reduced the level of C-reactive protein (CRP) but did not reduce the rate of POAF. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 69-72 32652935-14 2020 Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 96-99 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 63-66 33224343-6 2020 According to the above-mentioned results, rosuvastatin, fluvastatin, pitavastatin and atorvastatin were found to have stronger binding to CRP compared with the standard ligand phosphocholine (pKi = 14.55). Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 138-141 32428019-10 2020 Multiple logistic regression did show that compared to Atorvastatin-80mg, Rosuvastatin-40mg regime had poorer control of hs-CRP (A3OR = 1.45,p = 0.0202), higher (A3OR = 2.07) adverse effects, poorer safety profile (A3OR = 1.23), higher GERD/Gastritis (A3OR = 1.50) and poorer overall tolerability (A3OR = 1.50). Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 124-127 27756037-9 2016 Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. Rosuvastatin Calcium 100-103 C-reactive protein Homo sapiens 84-87 30790446-13 2019 C-reactive protein (CRP) was comparable between the groups at baseline, while at follow-up CRP was significantly lower in the rosuvastatin group compared to placebo [0.6 (+-0.5) mg/L vs. 2.6 (+-3.0) mg/L; p = 0.002]. Rosuvastatin Calcium 126-138 C-reactive protein Homo sapiens 91-94 30790446-14 2019 Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve microvascular function as assessed by IMR (Clinical Trials.gov NCT01582165, EUDRACT 2011-002630-39.3tcAZ). Rosuvastatin Calcium 8-20 C-reactive protein Homo sapiens 55-58 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Rosuvastatin Calcium 80-92 C-reactive protein Homo sapiens 166-169 26271127-0 2016 Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Rosuvastatin Calcium 24-36 C-reactive protein Homo sapiens 83-101 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Rosuvastatin Calcium 129-141 C-reactive protein Homo sapiens 26-29 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 142-160 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 162-165 26271127-8 2016 Our meta-analysis shows that rosuvastatin produces better reduction in CRP concentrations than atorvastatin at a dose ratio of 1/1 and 1/2 (rosuvastatin/atorvastatin), respectively. Rosuvastatin Calcium 29-41 C-reactive protein Homo sapiens 71-74 27144849-6 2016 RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). Rosuvastatin Calcium 139-151 C-reactive protein Homo sapiens 71-89 27058799-11 2016 CONCLUSIONS: Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 82-85 26311995-6 2015 CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 0-3 26311995-7 2015 However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 +- 6.32 vs 23.07 +- 7.47, P < 0.05). Rosuvastatin Calcium 87-99 C-reactive protein Homo sapiens 64-67 26311995-9 2015 CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 91-94 26311995-10 2015 Rosuvastatin was found to be more effective in decreasing CRP levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 58-61 25536316-0 2015 Rosuvastatin ameliorates inflammation, renal fat accumulation, and kidney injury in transgenic spontaneously hypertensive rats expressing human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 144-162 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 C-reactive protein Homo sapiens 76-79 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 125-128 25536316-2 2015 In addition, we found that rosuvastatin treatment of SHR-CRP transgenic rats can protect against pro-inflammatory effects of human CRP and also reduce cardiac inflammation and oxidative damage. Rosuvastatin Calcium 27-39 C-reactive protein Homo sapiens 131-134 25159238-9 2014 After rosuvastatin therapy, serum total cholesterol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein significantly decreased from 222 +- 18 to 142 +- 20 mg/dl, 148 +- 21 to 85 +- 18 mg/dl, and 1.7 +- 2.9 to 1.2 +- 3.1 mg/L, respectively (all p <0.01). Rosuvastatin Calcium 6-18 C-reactive protein Homo sapiens 111-129 23600368-8 2013 Rosuvastatin monotherapy and add-on ER-NA/LRPT groups were associated with 56% and 24% reduction in high-sensitivity C-reactive protein levels (hsCRP), respectively (P < 0.01 compared with baseline), while add-on fenofibrate was not associated with changes in hsCRP concentration. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 117-135 24614628-5 2014 Although not statistically significant, C-reactive protein was lower in the rosuvastatin than in the pravastatin group at the chronic stage (1.14+-1.21 vs. 7.67+-13.67 mg/l, P=0.051). Rosuvastatin Calcium 76-88 C-reactive protein Homo sapiens 40-58 24304551-7 2014 Patients with C-reactive protein >=2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mug/L vs 0.056 [0.018 to 0.241] mug/L; p = 0.04). Rosuvastatin Calcium 94-106 C-reactive protein Homo sapiens 14-32 25278982-8 2014 The effect of rosuvastatin on preventing CIN was greater in the subgroups of patients with diabetes, high-dose contrast medium, multivessel stents, high baseline C-reactive protein, and myocardial infarction. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 162-180 24410968-0 2014 Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 68-86 24410968-3 2014 Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 89-92 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 C-reactive protein Homo sapiens 7-10 24410968-8 2014 Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 160-163 24410968-9 2014 CONCLUSION: Rosuvastatin can protect against pro-inflammatory effects of human CRP in a manner that is not dependent on achieving a reduction in circulating levels of human CRP. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 79-82 24008003-0 2013 Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-80 24008003-11 2013 CONCLUSIONS: Six-month rosuvastatin therapy improves endothelial function and lowers CRP, C3, C4 and IC levels indicating possible favourable effects of this statin on the cardiovascular and immune system in SSc. Rosuvastatin Calcium 23-35 C-reactive protein Homo sapiens 85-88 22573476-8 2013 Intensified lipid-lowering therapy with RSV/EZT was associated with a greater decrease in low-density lipoprotein cholesterol levels compared with RSV (75.87 +- 31.64 vs 87.19 +- 31.7, P = .004), while no differential effect on triglyceride, high-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels was noted between groups. Rosuvastatin Calcium 40-43 C-reactive protein Homo sapiens 299-317 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 106-124 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 223-241 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 243-246 22697388-4 2012 A pivotal trial was the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which demonstrated significant reductions in cardiovascular morbidity and mortality in healthy individuals without elevated LDL cholesterol but with high levels of the inflammatory marker high-sensitivity C-reactive protein. Rosuvastatin Calcium 117-129 C-reactive protein Homo sapiens 346-364 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 126-129 22555227-0 2012 Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 37-55 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 121-139 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 141-144 22230323-3 2012 METHODS AND RESULTS: We performed a study to evaluate potential genetic determinants of CRP response using genome-wide genetic data from a total of 6766 participants of European ancestry randomly allocated to 20 mg/d of rosuvastatin or placebo in the JUPITER trial. Rosuvastatin Calcium 220-232 C-reactive protein Homo sapiens 88-91 22555227-8 2012 There was a trend towards improvement in CRP in the rosuvastatin group (-3.23; SD, 18.18) compared with the placebo group (+17.43; SD, 38.03); P value, 0.161. Rosuvastatin Calcium 52-64 C-reactive protein Homo sapiens 41-44 22555227-10 2012 These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity. Rosuvastatin Calcium 21-33 C-reactive protein Homo sapiens 58-61 22230323-4 2012 Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (P<0.001 for both) and essentially uncorrelated (r(2)<0.03). Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 52-55 22230323-9 2012 CONCLUSIONS: The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 62-65 21641360-0 2011 Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 21983163-8 2012 And also, both dosing regimens significantly decreased serum concentrations of CRP, which had an 18.3% reduction in once-daily dosing and a 16.7% reduction in alternate-day dosing of rosuvastatin (p>0.05). Rosuvastatin Calcium 183-195 C-reactive protein Homo sapiens 79-82 21856482-1 2011 BACKGROUND: The JUPITER trial showed that some patients with LDL-cholesterol concentrations less than 3 37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or more benefit from treatment with rosuvastatin, although absolute rates of cardiovascular events were low. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 151-169 21860701-1 2011 THE JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: an intervention trial evaluating rosuvastatin (JUPITER) study was a real breakthrough in primary cardiovascular disease prevention with statins, since it was conducted in apparently healthy individuals with normal levels of low-density lipoprotein cholesterol (LDL-C < 130 mg/dL) and increased inflammatory state, reflected by a high concentration of high-sensitivity C-reactive protein (hs-CRP >= 2 mg/L). Rosuvastatin Calcium 89-101 C-reactive protein Homo sapiens 427-445 21422984-3 2011 We examined the effect of pravastatin and rosuvastatin on CRP levels in 58 dyslipidemic HIV-infected patients. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 58-61 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 C-reactive protein Homo sapiens 72-90 22687786-11 2012 Correlation was found between changes in ROCK inhibition and changes in CRP in rosuvastatin 40 mg/day group (r=0.47, p<0.05). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 72-75 22687786-12 2012 CONCLUSION: These results demonstrate that high dose rosuvastatin exerts greater effects on LDL-C, ROCK activity, and CRP than low dose rosuvastatin. Rosuvastatin Calcium 53-65 C-reactive protein Homo sapiens 118-121 21792541-2 2011 Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier: that of prescribing statins for vascular events risk reduction based upon the baseline CRP levels in otherwise healthy adults. Rosuvastatin Calcium 111-123 C-reactive protein Homo sapiens 250-253 21742096-8 2011 CONCLUSIONS: When used in primary prevention among individuals with low-density lipoprotein <130 mg/dL and high-sensitivity C-reactive protein >=2 mg/L, rosuvastatin significantly reduced first MI, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death among whites and nonwhites. Rosuvastatin Calcium 159-171 C-reactive protein Homo sapiens 127-145 21562509-0 2011 Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 91-109 21641360-6 2011 Treatment with rosuvastatin led to a persistent decrease in CRP at 1 year and end of follow-up. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 60-63 21641360-11 2011 Treatment with rosuvastatin reduces CRP levels but has no effect on the progression and clinical events of AS. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 36-39 21310313-2 2011 BACKGROUND: The JUPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein (LDL) cholesterol levels. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 140-158 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 161-179 21257003-7 2011 Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 105-123 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Rosuvastatin Calcium 82-94 C-reactive protein Homo sapiens 123-141 21046291-5 2011 In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 231-234 20471117-7 2011 High-sensitivity C-reactive protein levels were less elevated in the rosuvastatin group than in the control group at 24 h after PCI. Rosuvastatin Calcium 69-81 C-reactive protein Homo sapiens 17-35 20971747-7 2011 CONCLUSION: In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk >=5%), but LDL-C levels not requiring pharmacologic treatment, rosuvastatin 20 mg significantly reduced major cardiovascular events. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 60-78 21135368-0 2010 Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 288-300 C-reactive protein Homo sapiens 150-168 21921413-4 2011 We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 96-114 21267417-9 2010 Rosuvastatin lowers CRP levels significantly. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 20-23 21135369-0 2010 Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 278-290 C-reactive protein Homo sapiens 140-158 21491734-5 2010 The use of CRP as a guide in primary prevention was tested for the first time in the JUPITER study, a large randomized trial comparing rosuvastatin 20 mg and placebo. Rosuvastatin Calcium 135-147 C-reactive protein Homo sapiens 11-14 21094359-0 2010 Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). Rosuvastatin Calcium 156-168 C-reactive protein Homo sapiens 108-126 21094359-1 2010 Plasma levels of high-sensitivity C-reactive protein (hsCRP) are an important predictor of cardiovascular disease, and achievement of lower targets of hsCRP with rosuvastatin treatment was associated with improved cardiovascular outcomes. Rosuvastatin Calcium 162-174 C-reactive protein Homo sapiens 34-52 21094359-8 2010 In conclusion, central obesity, low HDL cholesterol, and CRP polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with rosuvastatin. Rosuvastatin Calcium 166-178 C-reactive protein Homo sapiens 57-60 19351576-1 2010 BACKGROUND: The JUPITER trial has recently demonstrated an outstanding reduction of cardiovascular events by 20 mg rosuvastatin/day in subjects with high CRP who were apparently healthy at baseline. Rosuvastatin Calcium 115-127 C-reactive protein Homo sapiens 154-157 20580035-14 2010 The addition of exercise training to rosuvastatin treatment further lowered CRP and reduced the size of the inflammatory monocyte population, suggesting an additive anti-inflammatory effect of exercise. Rosuvastatin Calcium 37-49 C-reactive protein Homo sapiens 76-79 20946880-7 2010 A recent clinical study has shown that rosuvastatin reduces risk of ischemic stroke in patients with high plasma levels of the inflammatory marker C-reactive protein by 50%. Rosuvastatin Calcium 39-51 C-reactive protein Homo sapiens 147-165 20876499-4 2010 A recent randomized, clinical trial suggests that the use of rosuvastatin therapy in otherwise healthy patients with high-sensitivity C-reactive protein >2 mg/dL can reduce the risk of a first stroke by 50%. Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 134-152 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 100-118 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 120-123 20805548-0 2010 Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 144-162 20625281-4 2010 The Justification for the use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated a significant benefit of rosuvastatin in low-risk patients with no apparent vascular disease, low-density lipoprotein levels of less than 3.4 mmol/l, and elevated high sensitivity C-reactive protein. Rosuvastatin Calcium 158-170 C-reactive protein Homo sapiens 313-331 20805548-1 2010 CONTEXT: The Food and Drug Administration (FDA) recently approved rosuvastatin calcium for prevention of cardiovascular events in patients who have elevated levels of high-sensitivity C-reactive protein (hs-CRP) but not overt hyperlipidemia. Rosuvastatin Calcium 66-86 C-reactive protein Homo sapiens 184-202 20412373-0 2010 C-reactive protein lowering with rosuvastatin in the METEOR study. Rosuvastatin Calcium 33-45 C-reactive protein Homo sapiens 0-18 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 21-24 20412373-11 2010 CONCLUSIONS: Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL-C in low-risk subjects with normal baseline CRP levels and modest CIMT. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 41-44 20404379-0 2010 Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 67-85 20719717-3 2010 In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 68-86 20547900-1 2010 Rosuvastatin prevented ischemic stroke in healthy older adults with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-95 20404379-14 2010 CONCLUSION: In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events. Rosuvastatin Calcium 133-145 C-reactive protein Homo sapiens 106-124 20668802-10 2010 JUPITER represented a valid outcomes study but made a claim that rosuvastatin has special value in risk management because of decreased high sensitivity C-Reactive Protein. Rosuvastatin Calcium 65-77 C-reactive protein Homo sapiens 153-171 21547097-6 2010 Thus it appears that this pleiotropic effect of rosuvastatin may be responsible for part of its unusual effectiveness in reducing the risk of various cardiovascular endpoints found in JUPITER and calls into question the interpretation based only on LDL cholesterol and CRP changes. Rosuvastatin Calcium 48-60 C-reactive protein Homo sapiens 269-272 20152247-5 2010 Rosuvastatin treatment significantly lowered total (-36%, p <0.01) and low-density lipoprotein (-47%, p <0.001) cholesterol and C-reactive protein levels (-36%, p <0.05). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 134-152 20026779-0 2010 Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 85-103 20026779-6 2010 CONCLUSIONS: Rosuvastatin reduces by more than half the incidence of ischemic stroke among men and women with low levels of low-density lipoprotein cholesterol levels who are at risk because of elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 230-248 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 215-233 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 235-238 20146674-13 2010 In ROS group CRP had tendency to decrease but same tendency took place in control. Rosuvastatin Calcium 3-6 C-reactive protein Homo sapiens 13-16 24692836-18 2009 CONCLUSION: Rosuvastatin treatment was associated with significant reductions in plasma concentrations of TC, LDL-C, and TG, urine and plasma oxidative stress markers, and plasma hs-CRP in these hypercholesterolemic patients. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 182-185 19460829-4 2009 Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 20031900-0 2009 Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 185-203 20031900-1 2009 BACKGROUND: As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 280-298 19755356-1 2009 Rosuvastatin reduced venous thromboembolism in healthy older adults with elevated C-reactive protein levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 82-100 19329177-0 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Rosuvastatin Calcium 103-115 C-reactive protein Homo sapiens 13-31 19500485-0 2009 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 19656039-2 2009 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 2-14 C-reactive protein Homo sapiens 73-91 19332604-0 2009 Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 75-93 19306526-8 2009 The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. Rosuvastatin Calcium 131-143 C-reactive protein Homo sapiens 74-92 18481276-8 2009 The model was used to investigate how on-treatment CRP related to baseline CRP and estimated treatment effects with rosuvastatin. Rosuvastatin Calcium 116-128 C-reactive protein Homo sapiens 51-54 18481276-11 2009 There was also evidence of a dose-response relationship between CRP reductions from baseline and rosuvastatin. Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 64-67 19271272-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271273-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271274-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271275-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271276-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271277-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271278-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 18997196-0 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 18997196-9 2008 CONCLUSIONS: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Rosuvastatin Calcium 142-154 C-reactive protein Homo sapiens 115-133 18789009-6 2008 Treatment with rosuvastatin in moderate doses significantly suppressed activity of endogenous inflammation and oxidative stress by way of activation of antioxidant system of plasma, decrease of oxidation of fractions of lipoproteins, suppression of " nitrotirosine " stress, as well as partial inhibition of efficacy of action of secretory phospholipase A2, lowering of content of C-reactive protein and interleukin-6. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 381-399 19264695-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271446-0 2009 [Less vascular risk with rosuvastatin in elevated CRP]. Rosuvastatin Calcium 25-37 C-reactive protein Homo sapiens 50-53 19172709-1 2009 Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 76-94 20000881-5 2009 The reduction of CRP levels itself or as a statin-related pleiotropic effect has been assessed in different scenarios, including the acute phase of myocardial infarction; secondary prevention of cardiovascular diseases; special patient populations, such as diabetic patients; and finally in a primary prevention study (JUPITER [Justification for the Use of statins in primary Prevention: an Intervention Trial Evaluating Rosuvastatin]). Rosuvastatin Calcium 421-433 C-reactive protein Homo sapiens 17-20 21701608-3 2009 In healthy subjects with normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly decreased the incidence of cardiovascular events. Rosuvastatin Calcium 81-93 C-reactive protein Homo sapiens 61-79 19463128-4 2009 Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells. Rosuvastatin Calcium 43-55 C-reactive protein Homo sapiens 88-106 19436657-7 2009 In addition, rosuvastatin has been found effective in reducing small-dense LDL, C-reactive protein and in increasing HDL cholesterol levels. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 80-98